Recent coverage of Taysha Gene Therapies (TSHA) focuses on clinical data for TSHA-102 in Rett syndrome, highlighting a reported 100% responder rate and clean safety profile, as well as preparations for commercial-scale manufacturing and future regulatory filings.

At a recent share price of US$5.71, Taysha Gene Therapies has shown a 1 day share price return of 2.33% and a 90 day share price return of 26.05%. The 1 year total shareholder return of 124.80% and very large 3 year total shareholder return suggest momentum has been building despite a 5 year total shareholder return that is down 77.83%.

If this kind of biotech volatility interests you, it can be worth scanning for other healthcare and gene therapy opportunities using the 40 healthcare AI stocks

With TSHA trading at US$5.71 against analyst estimates around US$12.23 and an indicated intrinsic discount of roughly 87%, the key question is whether this gap reflects a genuine opportunity or whether the market is already pricing in future growth.

Most Popular Narrative: 53.3% Undervalued

With Taysha Gene Therapies at $5.71 against a narrative fair value of $12.23, the gap is wide enough that the underlying story matters.

The strategic focus on demonstrating clinically meaningful functional gains aligns with both regulatory expectations and caregiver priorities, potentially leading to strong market adoption post-approval, thereby impacting future net margins and earnings.

Want to see what sits behind that fair value gap? The narrative leans on rapid revenue expansion, a sharp turnaround in margins, and a premium earnings multiple baked into 2029.

Result: Fair Value of $12.23 (UNDERVALUED)

However, the story can change quickly if regulatory approvals are slower than analysts expect or if clinical trials fail to deliver the anticipated outcomes.

Another Angle On Valuation

While analyst targets and narrative fair value lean heavily on rapid revenue growth and margin improvement, the current P/B ratio tells a different story. TSHA trades at 7.7x book value, which is rich versus the US Biotechs average of 2.4x but lower than the peer average of 23.6x. That mix of expensive and cheap signals raises a simple question: how much risk are you really taking on to own this level of optimism?

To see how these P/B numbers tie back to cash flows and long term potential, it is worth scanning through the detailed valuation work in the See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With sentiment split between those focused on upside potential and those watching the risks, it makes sense to look at the numbers yourself and move quickly while the picture is fresh. To help frame both sides of the story, take a closer look at the 2 key rewards and 2 important warning signs

Looking for more investment ideas?

If you only stop at one stock, you risk missing opportunities that could fit your style better, so keep widening your field of view with targeted ideas.

• Spot potential breakouts early by scanning 24 elite penny stocks with strong financials where small price tags meet higher quality fundamentals.
• Strengthen your income focus by reviewing the 8 dividend fortresses and see which companies currently pair higher yields with robust profiles.
• Balance return potential with resilience by checking the 71 resilient stocks with low risk scores so you can focus on stocks with more controlled risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.